In conclusion, our present findings indicate that interference with mevalonate synthesis pathway using fluvastatin can selectively inhibit only some molecular mechanisms responsible for killing of tumor cells and that this inhibiting effect is less evident on FcγRIIIA/CD16-mediated NK cell triggering. Here, FCGR3A is linked to neoplasm.